German life sciences and technology company Merck KGaA (MRK: DE) has announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.
These analyses reinforce the proven survival benefits of the PD-L1 antibody Bavencio (avelumab) in the first-line maintenance setting for patients with locally advanced or metastatic urothelial carcinoma (UC).
"A reference point for outcomes of ongoing and future clinical trials in advanced bladder cancer"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze